Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Novavax is a commercial-stage biotechnology company that has received FDA approval and EC Marketing Authorization for their COVID vaccine Nuvaxovid and has entered a commercialization partnership with Sanofi for this vaccine. Their product pipeline, particularly the in-house development of a live attenuated flu/COVID combo vaccine and their Matrix-M adjuvant technology, could drive long-term value for the company. The efficacy and tolerability data for Nuvaxovid compared to the currently licensed mRNA vaccines could also contribute to their success in capturing market share in the COVID vaccine market.

Bears say

Novavax is facing several challenges, including potential competition in the maternal vaccine market, limited evidence of efficacy for their COVID-19 vaccine compared to other platforms, and potential vaccine hesitancy among the general population. Despite the recent ACIP recommendation for pregnant individuals to receive COVID-19, flu, and Tdap vaccinations, Novavax may struggle to capture a significant market share due to the dominance of Sanofi in the flu market and the targeted demographic for the two vaccines already overlapping. However, with the potential development of a monoclonal antibody approach similar to Invivyd's, Novavax may still have the opportunity to compete in the evolving COVID protection landscape. It will be important to closely monitor the uptake of COVID-19 vaccines and any potential developments in alternative prophylaxis approaches.

Novavax (NVAX) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 6 analysts, Novavax (NVAX) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.